# Strategikon Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/strategikon-pharma

- Industry: Healthcare IT
- Headquarters: San Rafael, US
- Website: www.strategikonpharma.com
- Latest round: Series A (Apr 22, 2021)
- Investors on record: 8

## About

Strategikon Pharma Inc. specializes in AI-driven software-as-a-service solutions for clinical trials and the pharmaceutical industry, enhancing operational efficiency through its innovative products.Founded in 2016 in San Rafael, US, Strategikon Pharma Inc. focuses on providing advanced software solutions for clinical trials. The company was co-founded by Anca Copaescu and Paulo Carvalho, with Anca Copaescu currently serving as CEO. Strategikon has completed 2 significant deals, with the most recent deal taking place on April 22, 2021.Strategikon delivers a suite of AI-driven software-as-a-service (SaaS) solutions tailored for the clinical trials and pharmaceutical industries. Its flagship products include VISION, Clinical Maestro, CORE, and LEAD, designed to streamline and enhance various aspects of clinical study management. VISION acts as a centralized hub for vendor management, providing real-time insights into vendor qualifications and performance. Clinical Maestro automates budgeting, contract management, and vendor selection, while CORE specializes in precise clinical trial budgeting. LEAD automates workflows related to clinical study budgets, enabling users to monitor project timelines and compliance. These solutions cater primarily to biopharmaceutical companies, contract research organizations (CROs), and service providers in North America, Europe, and parts of Asia.Strategikon operates on a subscription-based revenue model, deriving income from fees associated with the use of its products, including VISION, Clinical Maestro, CORE, and LEAD. Clients typically engage in long-term partnerships through annual subscriptions that provide access to a comprehensive range of features. Additionally, the company may form strategic partnerships with organizations seeking tailored solutions, diversifying its revenue streams while strengthening client relationships.In April 2021, Strategikon Pharma Inc. raised an undisclosed amount in Series A funding led by Osage Venture Partners and included participation from Wing Venture Capital and Bascom Ventures, as well as returning investors. The company plans to utilize these funds to expand its global presence in Europe and Asia, develop new applications, and enhance the existing Clinical Maestro™ ecosystem. Furthermore, it aims to broaden its professional services to ensure a superior customer experience.

## Funding rounds

- Series A, Apr 22, 2021 — Band of Angels, Saratoga Ventures, Tech Coast Angels, Golden Seeds, Life Science Angels, Inc., Wing, Osage Venture Partners, Bascom Ventures

## Investors

- Band of Angels (https://capitalatlas.ai/funds/band-of-angels) — Series A
- Saratoga Ventures (https://capitalatlas.ai/funds/saratoga-ventures) — Series A
- Tech Coast Angels — Series A
- Golden Seeds (https://capitalatlas.ai/funds/golden-seeds) — Series A
- Life Science Angels, Inc. — Series A
- Wing (https://capitalatlas.ai/funds/wing) — Series A
- Osage Venture Partners (https://capitalatlas.ai/funds/osage-venture-partners) — Series A
- Bascom Ventures — Series A